Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.73 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16020629 | 0.96 | FGFR1 (0.93) | FGFR1CYP3A4CYP2D6SLC22A6 | |
| SCHEMBL20644448 | 0.92 | FGFR1 (0.85) | FGFR1CYP3A4CYP2D6SLC22A6 | |
| SCHEMBL173078 | 0.89 | FGFR1 (0.80) | FGFR1CYP3A4CYP2D6SLC22A6 | |
| SCHEMBL13114436 | 0.88 | FGFR1 (0.79) | FGFR1CYP3A4CYP2D6SLC22A6 | |
| SCHEMBL20644361 | 0.88 | FGFR1 (0.79) | FGFR1CYP3A4CYP2D6SLC22A6 | |
| SCHEMBL19470287 | 0.88 | FGFR1 (0.78) | FGFR1CYP3A4CYP2D6SLC22A6 | |
| Tenofovir Exalidex SCHEMBL8268123 | 0.85 | CYP3A4 (0.98) | FGFR1CYP3A4CYP2D6 | |
| Tenofovir Exalidex SCHEMBL2299893 | 0.85 | CYP3A4 (0.98) | FGFR1CYP3A4CYP2D6 | |
| SCHEMBL23014999 | 0.84 | CYP3A4 (0.97) | CYP3A4CYP2D6 | |
| SCHEMBL23015000 | 0.84 | CYP3A4 (0.97) | CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| US-9649321-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-10 | — | — | US | disclosed |
| US-9206208-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150051174-A1 | Phosphonate Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | disclosed |
| US-8889658-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-18 | — | — | US | disclosed |
| US-8710030-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140045794-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-13 | — | — | US | disclosed |
| US-8642577-B2 | Compounds, compositions and methods for the treatment of poxvirus infections | CHIMERIX, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120164104-A1 | Composition and Methods of Treating Viral Infections and Viral Induced Tumors | CHIMERIX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120058975-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-03-08 | — | — | US | disclosed |
| US-8008308-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-08-30 | — | — | US | disclosed |
| US-20110015149-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS | CHIMERIX, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20100173870-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-07-08 | — | — | US | disclosed |
| US-7687480-B2 | Alkylpropanediol derivatized adefovir; reduced toxicity; osteoporosis, bone metabolism disorders , cancer, viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-30 | — | — | US | disclosed |
| US-7452898-B2 | Use of 1-O-octadecylpropanediol-3-cidofovir to treat viral diseases such as HIV, influenza, herpes virus, cytomegalovirus, hepatitis virus, Epstein-Barr virus, varicella zoster virus, orthopox virus, ebola virus and papilloma virus | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080103115-A1 | Alkylpropanediol derivatized adefovir; reduced toxicity; osteoporosis, bone metabolism disorders , cancer, viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-05-01 | — | — | US | disclosed |
| US-20070003516-A1 | Compounds, compositions and methods for the treatment of poxvirus infections | EMERGENT BIODEFENSE OPERATIONS LANSING LLC | 2007-01-04 | — | — | US | disclosed |
| US-20070003608-A1 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | CHIMERIX, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051174-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | FGFR1 1716/4885CYP3A4 2408/4885CYP2D6 3148/4885 |
| US-20140045794-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | FGFR1 1716/4885CYP3A4 2408/4885CYP2D6 3148/4885 |
| US-20080103115-A1 | Alkylpropanediol derivatized adefovir; reduced toxicity; osteoporosis, bone metabolism disorders , cancer, viral infections | APRT, AASDHPPT, APOBEC3G | FGFR1 2772/4885CYP3A4 43/4885CYP2D6 299/4885 |
| US-20070003516-A1 | Compounds, compositions and methods for the treatment of poxvirus infections | IFNG, POLI, STING1 | FGFR1 4780/4885CYP3A4 3783/4885CYP2D6 3385/4885 |
| US-20110015149-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS | ACE, CYP27A1, LIPC | FGFR1 3111/4885CYP3A4 25/4885CYP2D6 28/4885 |
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | FGFR1 1716/4885CYP3A4 2408/4885CYP2D6 3148/4885 |
| US-20120058975-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | FGFR1 1716/4885CYP3A4 2408/4885CYP2D6 3148/4885 |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | FGFR1 1716/4885CYP3A4 2408/4885CYP2D6 3148/4885 |
| US-20070003608-A1 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | ACE, CYP27A1, LIPC | FGFR1 3111/4885CYP3A4 25/4885CYP2D6 28/4885 |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | HAVCR2, EIF2AK2, TSLP | FGFR1 4116/4885CYP3A4 2858/4885CYP2D6 3190/4885 |
| US-20120164104-A1 | Composition and Methods of Treating Viral Infections and Viral Induced Tumors | HAVCR2, IRF3, CCL5 | FGFR1 1945/4885CYP3A4 2550/4885CYP2D6 3089/4885 |
| US-20100173870-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | FGFR1 1716/4885CYP3A4 2408/4885CYP2D6 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.